The Weekly Roundup: September 1-5

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Labor Day Spotlights Hidden Contact Allergens

Cases of dermatitis in workers and consumers alike show how allergen exposure transcends occupational boundaries.

Dermatology Conferences and Meetings Calendar: September 2025

Dermatology Times has compiled a list of dermatological meetings taking place during the month of September.

Biofrontera Completes Ameluz Phase 2b Trial for Moderate to Severe Acne

Biofrontera Inc. advances acne treatment with aminolevulinic acid hydrochloride gel, completing a phase 2b study for moderate to severe cases.

Adherence Challenges Take Center Stage in Psoriasis Management

Experts in Miami Beach emphasized that adherence often drives biologic choice more than efficacy in real-world psoriasis care.

Replimune Prepares for Type A Meeting With FDA on RP1

The FDA cited concerns about patient population heterogeneity and confirmatory trial design.

Almirall and Absci Expand Collaboration to Accelerate AI-Powered Drug Discovery for Skin Diseases

Almirall and Absci enhance their collaboration, leveraging AI to revolutionize drug discovery for challenging dermatological conditions and improve patient outcomes.

Stepwise Care in Chronic Spontaneous Urticaria

Explore effective strategies for managing CSU, including tailored therapies and the latest treatment advancements for optimal patient care.

Beyond Bad Habits: Understanding and Treating Dermatillomania and Trichotillomania

Sofia Wenzler, PhD, addresses misconceptions about dermatillomania (skin picking) and trichotillomania (hair pulling), advocating for compassionate care and accessible treatment for BFRBs.

Selective JAK Inhibition With Deuruxolitinib Restores Hair Growth in Alopecia Areata

Vimal Prajapati, MD, FRCPC, DABD, reviews the mechanism of action, clinical trial outcomes, monitoring considerations, and safety profile of recently available deuruxolitinib.

Happy Head Launches World's First DNA-Powered Hair Growth System

Happy Head's StrandIQ system revolutionizes hair loss treatment with personalized genetic analysis, enhancing hair growth and scalp health for individuals.

Saving for the High Cost of College: Understanding 529 Plans

Discover how 529 plans empower dermatologists to save for college, offering tax benefits and new Roth IRA transfer options for added flexibility.

Allergan's New Campaign and Data Report Fights Misinformation on Hyaluronic Acid Fillers

Allergan Aesthetics has launched an initiative to educate on HA fillers, emphasizing safety and natural results, backed by expert insights and patient satisfaction data.

Addressing Misconceptions in Skin of Color Dermatology

Explore the latest insights on skin and scalp care, focusing on cultural sensitivity and early intervention for diverse dermatological needs.

HS TRUTHS Spotlights Hidden Patient Realities

Research shows it can take 7 to 10 years for individuals with HS to receive an accurate diagnosis.

Equity in Melanoma Survival Masks Inequity in Diagnosis

While survival rates were similar across income levels, lower-income patients consistently presented with more aggressive disease.

Arcutis Submits sNDA for Roflumilast Cream 0.3% to Treat Plaque Psoriasis in Patients as Young as 2

Arcutis Biotherapeutics seeks FDA approval for Zoryve cream to treat plaque psoriasis in children as young as 2, addressing a critical treatment gap.

How the COVID-19 Pandemic Disrupted Melanoma Diagnosis and Treatment

COVID-19 significantly delayed melanoma diagnoses and treatments, leading to increased disease severity and advanced cases, highlighting urgent health care needs.

Shared Decision-Making in Hair and Scalp Care

Chesahna Kindred, MD, MBA, FAAD, highlights the need for tailored dermatological care for textured hair, addressing misdiagnoses and promoting collaboration with hairstylists.

EAACI Report Explores Pediatric Chronic Urticaria Diagnosis and Treatment Patterns

EAACI's report highlights current practices and challenges in diagnosing and managing chronic urticaria in pediatric patients, emphasizing the need for improved education and resources.

Integrating Deuruxolitinib Into Clinical Practice for Severe Alopecia Areata

Vimal Prajapati, MD, FRCPC, DABD, highlighted key findings from the THRIVE-AA trials, noting the efficacy of deuruxolitinib8 mg BID, its favorable safety profile, and its positioning alongside other JAK inhibitors.

French Survey Highlights Gaps in Chronic Hand Eczema Care

Most physicians continue to prescribe topical corticosteroids despite prior treatment failure.

Chronic Spontaneous Urticaria: Evidence-Based Management Update

Explore the latest strategies for managing CSU, including personalized therapies and updated 2025 guidelines for effective treatment.

How Dermatologists Can Treat the Mind-Body Connection in BFRBs

Sofia Wenzler, PhD, highlights the vital role dermatologists play in treating body-focused repetitive behaviors like skin picking and hair pulling.

Putting Progress Into Practice for Patients With Vitiligo: Part 1

In part 1 of this Case-Based Roundtable supplement, Seemal Desai, MD, FAAD; Ted Lain, MD, MBA, FAAD; and Pearl Grimes, MD, FAAD, discuss real-world vitiligo scenarios, offering diagnostic insights, therapeutic strategies, and practical pearls from their own experiences.

Thermage Surpasses 5 Million Aesthetic Treatments, Solta Medical Announces

Thermage FLX achieves 5 million treatments, showcasing its trusted non-surgical skin tightening technology for smoother, youthful skin.

CAGE Bio Reports Strong Phase 2b Results for CGB-500 in AD

The study found that 59% of patients achieved IGA treatment success, surpassing other topical therapies.

Beyond Voluntourism: A Sustainable Approach to Global Medical Missions

Explore how dermatology-focused global medical missions can move beyond short-term “voluntourism” by fostering sustainable, collaborative partnerships that prioritize education, capacity building, and alignment with host country needs.

Model-Informed Drug Development: A Case Study in the Discontinued Ligelizumab for CSU

Explore how model-informed drug development shapes ligelizumab's journey in treating chronic spontaneous urticaria, despite its eventual discontinuation.

Dupilumab in Omalizumab-Resistant Chronic Spontaneous Urticaria: Early Pilot Data

Explore the potential of dupilumab for treating omalizumab-resistant chronic spontaneous urticaria, offering new hope for affected patients.